these four are signficant players in the genome sequencing market, but RHHB stock price hasn't take off in the same way, and Agilent is way out in front.
Does this make RHHB a good buy, or, is there something wrong, and making the others a better prospect? Is Agilent a sell?
Does this make RHHB a good buy, or, is there something wrong, and making the others a better prospect? Is Agilent a sell?
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。